NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout

    India
    Business
    World
    Politics
    Sports
    Technology
    Entertainment
    Auto
    Lifestyle
    Inspirational
    Career
    Bengaluru
    Delhi
    Mumbai

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
    Home / News / Business News / Dr Reddy's Q2 profit rises 33% YoY to Rs. 1,480cr
    Next Article
    Dr Reddy's Q2 profit rises 33% YoY to Rs. 1,480cr
    Dr. Reddy's shares settled at Rs. 5,397.30 on NSE, down 0.45% on October 27

    Dr Reddy's Q2 profit rises 33% YoY to Rs. 1,480cr

    By Rishabh Raj
    Oct 27, 2023
    05:30 pm

    What's the story

    Dr Reddy's Laboratories experienced a 33% year-on-year (YoY) rise in consolidated net profit for the July-September quarter, reaching Rs. 1,480 crore.

    In Q2 of the previous year, the company recorded a net profit of Rs. 1,112.8 crore.

    Revenue from operations during Q2 experienced a 9% YoY increase, totaling Rs. 6,880 crore. In Q2 of the previous year, the pharma major posted a revenue of Rs. 6,305.7 crore.

    Details

    EBITDA margin at 31.7%

    EBITDA stood at Rs. 2,181.3 crore, while the EBITDA margin was 31.7% vs 30.6% in the previous year's corresponding quarter.

    In Q2 FY24, the gross margin was 58.7%, representing a YoY decrease of approximately 40 basis points (bps) compared to 59.1% in Q2 FY23.

    This decline was primarily due to slightly unfavorable price changes in certain products and a change in product mix, but it was partially offset by a positive impact from foreign exchange rates, revealed an exchange filing.

    What Next?

    Growth factors

    Co-Chairman and MD, GV Prasad said, "We delivered another quarter of strong results with highest ever sales and profits, driven by market share gains and momentum in our US generics business and robust growth in Europe."

    "We are continuing to strengthen our pipeline both organically and through business development to drive growth and create differentiation."

    Dr. Reddy's shares closed nearly unchanged on the BSE following the results announcement on Friday.

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Latest
    Stock Market

    Latest

    'Sirens,' 'Nine Perfect Strangers': Your OTT watchlist this week Nicole Kidman
    'Fear Street: Prom Queen': Cast, plot, release details OTT releases
    IPL 2025, LSG vs SRH: How the Impact Players fared  Sunrisers Hyderabad (SRH)
    Microsoft employee disrupts Nadella's keynote: What's behind the protest? Satya Nadella

    Stock Market

    Sensex slips 483 points, Nifty settles near 19,510 mark Nifty
    US defense stocks surge amid Israel-Hamas war United States of America
    Nifty Realty Index jumps 5% to reach 15-year high Business
    Sensex climbs 567 points, Nifty settles near 19,690 mark Nifty
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2025